Hyzetimibe Tablet Solid Dispersion Stability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Hyzetimibe, a cholesterol-lowering drug, faces challenges due to its strong electrostatic adsorption, poor solubility, and sensitivity to temperature and humidity, leading to stability and absorption issues, which complicates its formulation and bioavailability.
Innovation Solution
A hyzetimibe tablet preparation method involving a solid dispersion composition with povidone, where hyzetimibe is dissolved in an organic solvent containing povidone and then mixed with adjuvants, followed by granulation and tabletting, to address electrostatic adsorption and crystal form transformation, while incorporating antioxidants like butylated hydroxytoluene to enhance stability.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If hyzetimibe is micronized to improve dissolution and bioavailability, then drug absorption is improved, but electrostatic adsorption is intensified and contact area with moisture and air increases, resulting in product instability
Solution Approach 1:
The patent uses a surfactant (sodium dodecyl sulfate) as an intermediary substance to reduce the strong electrostatic adsorption of hyzetimibe particles. This mediator prevents particle aggregation during micronization while controlling contact with moisture and air, thereby maintaining both improved bioavailability through fine particle size and product stability during storage.
Solution Approach 2:
The patent optimizes the particle size parameters of hyzetimibe to a specific range (D90: 3-10 μm, D50: 1.5-5 μm) to balance dissolution improvement with stability maintenance. By precisely controlling these physical parameters, the patent achieves enhanced bioavailability while minimizing the adverse effects of intensified electrostatic adsorption and increased moisture contact.
2Manufacturing precision
If particle size of hyzetimibe is reduced to improve dissolution, then bioavailability increases, but electrostatic adsorption intensifies and contact with moisture and air increases, causing instability
Solution Approach 1:
The surfactant sodium dodecyl sulfate acts as a protective intermediary that coats the micronized hyzetimibe particles, preventing direct contact between the drug particles and moisture/air. This intermediary layer maintains crystal form stability while allowing the fine particle size to enhance dissolution rate and bioavailability.
Solution Approach 2:
The patent creates a composite structure where hyzetimibe particles are combined with surfactant molecules forming a stable dispersion system. This composite material approach allows the drug to maintain its fine particle size for improved dissolution while the surfactant matrix protects the crystal structure from degradation.
3Ease of manufacture
If hyzetimibe is prepared by ethanol granulation without antioxidant, then processing is simplified, but impurities increase faster due to amorphous form having higher energy and greater contact with moisture and oxidants
Solution Approach 1:
The antioxidant (butylated hydroxytoluene) serves as a chemical intermediary that intercepts oxidants before they can react with the amorphous hyzetimibe regions. This protective mediator allows the use of simplified ethanol granulation processing while preventing oxidation-induced impurity formation during storage.
Solution Approach 2:
The antioxidant is incorporated into the formulation beforehand to provide preemptive protection against oxidation. This prior cushioning approach ensures that when the tablet is stored, the antioxidant is already in position to protect the amorphous drug regions from oxidant attack, preventing impurity formation without complicating the manufacturing process.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The method improves bioavailability, stability, and commercial manufacturing feasibility of hyzetimibe tablets by maintaining the drug in an amorphous form, ensuring high yield and reduced impurity formation during storage.
Implementation Method 1
A hyzetimibe tablet preparation method involving a solid dispersion composition with povidone, where hyzetimibe is dissolved in an organic solvent containing povidone and then mixed with adjuvants
Implementation Method 2
The method improves bioavailability, stability, and commercial manufacturing feasibility of hyzetimibe tablets by maintaining the drug in an amorphous form
Implementation Method 3
by adding an appropriate amount of an antioxidant such as butylated hydroxytoluene in the aqueous or organic solvent prescription, degradation into impurities can be effectively decreased
Implementation Method 4
an appropriate amount of surfactant such as Tweens or sodium dodecyl sulfate can usually be added into formulations
Data Source
AI summary
An HS-25 tablet, an HS-25 solid dispersion composition, a preparation method therefor and usage thereof. The HS-25 tablet is made by using HS-25 and excipients for wet granulation, drying, granulating and tablet pressing.